Frost & Sullivan releases 'Market Research on Innovative Drugs for Oncology and Metabolic Diseases'

In China and globally, the incidence of tumors continues to increase, becoming a major threat to human health. Over the past decade, small molecule targeted drugs have played a crucial role in tumor treatment. For example, EGFR-TKI drugs are of great significance in the treatment of non-small cell lung cancer with EGFR mutations, evolving from the first-generation EGFR-TKI gefitinib to the current third-generation ones such as osimertinib; in breast cancer, SERD drugs can treat ER/PR-positive breast cancer by inhibiting estrogen receptors. Small molecule drugs also play an important role in metabolic diseases such as gout, for instance, URAT1 inhibitors can inhibit the reabsorption of uric acid, thereby reducing blood uric acid levels. Based on research into the markets for tumors and metabolic diseases, Frost & Sullivan (Frost & Sullivan) has released relevant industry reports.